Aquestive Therapeutics Inc
AQST5.990USD
+0.020+0.34%
Cierre 12/26, 16:00（ET）Cotizaciones retrasadas 15 min
728.73MCap. mercado
PérdidaP/E TTM
Más Datos de Aquestive Therapeutics Inc Compañía
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Información de Aquestive Therapeutics Inc
Símbolo de cotizaciónAQST
Nombre de la empresaAquestive Therapeutics Inc
Fecha de salida a bolsaJul 25, 2018
Director ejecutivoBarber (Daniel R)
Número de empleados142
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 25
Dirección30 Technology Dr
CiudadWARREN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal07059-5166
Teléfono19089411900
Sitio Webhttps://aquestive.com/
Símbolo de cotizaciónAQST
Fecha de salida a bolsaJul 25, 2018
Director ejecutivoBarber (Daniel R)
Ejecutivos de Aquestive Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Daniel Barber
Mr. Daniel Barber
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.76M
-4.97%
Ms. Lori J. Braender, J.D.
Ms. Lori J. Braender, J.D.
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
649.24K
+36.11%
Mr. Peter E. Boyd
Mr. Peter E. Boyd
Senior Vice President - Information Technology, Human Resources and Communications
Senior Vice President - Information Technology, Human Resources and Communications
288.11K
+7.46%
Dr. Carl N. Kraus, M.D.
Dr. Carl N. Kraus, M.D.
Chief Medical Officer
Chief Medical Officer
282.48K
-6.70%
Ms. Cassie Jung
Ms. Cassie Jung
Chief Operating Officer
Chief Operating Officer
239.09K
-15.12%
Ms. Sherry Korczynski
Ms. Sherry Korczynski
Chief Commercial Officer
Chief Commercial Officer
181.86K
+15.94%
Dr. Gregory B. Brown, M.D.
Dr. Gregory B. Brown, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
75.08K
--
Dr. Marco Taglietti, M.D.
Dr. Marco Taglietti, M.D.
Independent Director
Independent Director
--
--
Mr. Timothy E. Morris, CPA
Mr. Timothy E. Morris, CPA
Independent Director
Independent Director
--
--
Ms. Stephanie Carrington
Ms. Stephanie Carrington
Investor Relations
Investor Relations
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Daniel Barber
Mr. Daniel Barber
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.76M
-4.97%
Ms. Lori J. Braender, J.D.
Ms. Lori J. Braender, J.D.
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
649.24K
+36.11%
Mr. Peter E. Boyd
Mr. Peter E. Boyd
Senior Vice President - Information Technology, Human Resources and Communications
Senior Vice President - Information Technology, Human Resources and Communications
288.11K
+7.46%
Dr. Carl N. Kraus, M.D.
Dr. Carl N. Kraus, M.D.
Chief Medical Officer
Chief Medical Officer
282.48K
-6.70%
Ms. Cassie Jung
Ms. Cassie Jung
Chief Operating Officer
Chief Operating Officer
239.09K
-15.12%
Ms. Sherry Korczynski
Ms. Sherry Korczynski
Chief Commercial Officer
Chief Commercial Officer
181.86K
+15.94%
Desglose de ingresos
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
Ex-United States
5.11M
0.00%
United States
4.89M
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: lun., 17 de nov
Actualizado: lun., 17 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Crestline Investors, Inc.
8.04%
RTW Investments L.P.
5.12%
BlackRock Institutional Trust Company, N.A.
4.82%
The Vanguard Group, Inc.
4.64%
Perceptive Advisors LLC
3.08%
Otro
74.29%
Accionistas
Accionistas
Proporción
Crestline Investors, Inc.
8.04%
RTW Investments L.P.
5.12%
BlackRock Institutional Trust Company, N.A.
4.82%
The Vanguard Group, Inc.
4.64%
Perceptive Advisors LLC
3.08%
Otro
74.29%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
17.59%
Hedge Fund
15.35%
Investment Advisor/Hedge Fund
14.96%
Individual Investor
4.78%
Research Firm
3.60%
Private Equity
3.16%
Venture Capital
2.10%
Pension Fund
0.13%
Bank and Trust
0.11%
Otro
38.23%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
290
68.88M
51.65%
+53.83K
2025Q3
292
69.42M
52.46%
+17.93M
2025Q2
259
51.52M
60.81%
+3.12M
2025Q1
254
48.51M
53.81%
-4.93M
2024Q4
235
47.80M
61.37%
-3.43M
2024Q3
221
51.10M
56.03%
+7.58M
2024Q2
183
43.39M
51.75%
+1.05M
2024Q1
153
42.09M
27.96%
+16.79M
2023Q4
116
23.79M
35.83%
+799.63K
2023Q3
117
22.90M
31.32%
+3.82M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Crestline Investors, Inc.
9.81M
8.13%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.89M
4.88%
+448.94K
+8.25%
Jun 30, 2025
The Vanguard Group, Inc.
4.33M
3.59%
+254.95K
+6.26%
Jun 30, 2025
Perceptive Advisors LLC
2.19M
1.82%
-1.54M
-41.23%
Jun 30, 2025
Armistice Capital LLC
2.75M
2.28%
+2.75M
--
Sep 30, 2024
Geode Capital Management, L.L.C.
1.98M
1.64%
+276.30K
+16.25%
Jun 30, 2025
Barber (Daniel R)
1.76M
1.46%
-91.74K
-4.97%
Sep 26, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.97%
Federated Hermes MDT Small Cap Core ETF
0.41%
iShares Micro-Cap ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
Vanguard US Momentum Factor ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
ProShares Hedge Replication ETF
0.02%
ProShares UltraPro Russell2000
0.02%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.97%
Federated Hermes MDT Small Cap Core ETF
Proporción0.41%
iShares Micro-Cap ETF
Proporción0.11%
ProShares Ultra Nasdaq Biotechnology
Proporción0.09%
Invesco Nasdaq Biotechnology ETF
Proporción0.08%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.04%
Vanguard US Momentum Factor ETF
Proporción0.03%
iShares Russell 2000 Value ETF
Proporción0.02%
ProShares Hedge Replication ETF
Proporción0.02%
ProShares UltraPro Russell2000
Proporción0.02%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Aquestive Therapeutics Inc?
Los cinco principales accionistas de Aquestive Therapeutics Inc son:
Crestline Investors, Inc. posee 9.81M acciones, lo que representa el 8.13% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 5.89M acciones, lo que representa el 4.88% del total de acciones.
The Vanguard Group, Inc. posee 4.33M acciones, lo que representa el 3.59% del total de acciones.
Perceptive Advisors LLC posee 2.19M acciones, lo que representa el 1.82% del total de acciones.
Armistice Capital LLC posee 2.75M acciones, lo que representa el 2.28% del total de acciones.
Crestline Investors, Inc. posee 9.81M acciones, lo que representa el 8.13% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 5.89M acciones, lo que representa el 4.88% del total de acciones.
The Vanguard Group, Inc. posee 4.33M acciones, lo que representa el 3.59% del total de acciones.
Perceptive Advisors LLC posee 2.19M acciones, lo que representa el 1.82% del total de acciones.
Armistice Capital LLC posee 2.75M acciones, lo que representa el 2.28% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Aquestive Therapeutics Inc?
Los tres principales tipos de accionista de Aquestive Therapeutics Inc son:
Crestline Investors, Inc.
RTW Investments L.P.
BlackRock Institutional Trust Company, N.A.
Crestline Investors, Inc.
RTW Investments L.P.
BlackRock Institutional Trust Company, N.A.
¿Cuántas instituciones poseen acciones de Aquestive Therapeutics Inc (AQST)?
A fecha de 2025Q4, 290 instituciones poseen acciones de Aquestive Therapeutics Inc, con un valor de mercado combinado de aproximadamente 68.88M, lo que representa el 51.65% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -0.81%.
¿Cuál es la mayor fuente de ganancias de Aquestive Therapeutics Inc?
El FY2025Q2, el segmento empresarial -- generó la ganancia más alta para Aquestive Therapeutics Inc, ascendiendo a -- y representando el --% de la ganancia total.
